About the Partner
Signal Transduction and Targeted Therapy is sponsored by West China Hospital, Sichuan University.
West China Hospital was established in 1892 by the joint efforts of Christian missionaries from the United States, Great Britain, and Canada. After 120 years of development, particularly during the reform and opening-up period, West China Hospital has become a comprehensive medical teaching and research center with diverse disciplines, abundant faculty resources, advanced medical techniques, modern medical equipment, and strong potential in medical research.
West China Hospital is one of the largest single-site hospitals in the world and a leading medical center of West China, treating complicated and severe cases, especially in the fields of living donor liver transplantation, severe acute pancreatitis, and clinical anesthesia. The hospital has 4,800 beds and covers an area of more than 470,000 sq m and service area of 400,000 sq m. It has more than 7,800 medical staff working among 38 clinical departments and 16 non-clinical and laboratory departments.
For more information about West China Hospital, please visit the website http://english.cd120.com/
State Key Laboratory of Biotherapy (SKLB), belongs to the West China Hospital, Sichuan University. The SKLB was established in 2005 and is sponsored by the Ministry of Sciences and Technology. It was selected as one of the National Research and Development (R&D) Platforms for Novel Drugs founded by the Ministry of Sciences and Technology as well as the Ministry of Health in 2008. In 2013, the SKLB became the National Collaborative Innovation Center of Biotherapy, which is supported by the 2011 plan managed by the Ministry of Education and the Ministry of Finance. In 2014, it was supported by another large-scale project called the National Major Infrastructure for Biotherapy and Translational Medicine, in which the government will invest roughly $200 million.
The SKLB is now becoming a highly regarded, comprehensive, and multidisciplinary research center in China. Through the seamless integration of basic science research, preclinical development, and translational and clinical medicine, an efficient and fully integrated technological chain for the discovery and development of innovative drug candidates has been established in a single institute. Part of the mission of this Platform is to improve the treatment of major human diseases such as cancer, cardiovascular diseases, obesity, diabetes mellitus, infectious diseases (hepatitis, AIDS, tuberculosis, etc.), inflammatory diseases, neurological diseases, and chronic autoimmune diseases. With emphasis on more than 200 important targets, hundreds of projects in basic science research and the development of biologic drugs (such as gene and cell therapy, vaccines, monoclonal antibodies, recombinant proteins, etc.), synthetic small molecule drugs, and small molecule natural products are currently ongoing.
For more information about SKLB, please visit the website http://sklb.scu.edu.cn/.